{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:07:24Z","timestamp":1789592844219,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Fosfomycin\/tobramycin for inhalation (FTI), a unique, broad-spectrum antibiotic combination, may have therapeutic potential for patients with cystic fibrosis (CF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate safety and efficacy of FTI (160\/40 mg or 80\/20 mg), administered twice daily for 28 days versus placebo, in patients greater than or equal to 18 years of age, with CF, chronic Pseudomonas aeruginosa (PA) airway infection, and FEV1 greater than or equal to 25% and less than or equal to 75% predicted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This double-blind, placebo-controlled, multicenter study assessed whether FTI\/placebo maintained FEV1 % predicted improvements achieved following a 28-day, open-label, run-in course of aztreonam for inhalation solution (AZLI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>A total of 119 patients were randomized to FTI (160\/40 mg: n = 41; 80\/20 mg: n = 38) or placebo (n = 40). Mean age was 32 years and mean FEV1 was 49% predicted at screening. Relative improvements in FEV1 % predicted achieved by the AZLI run-in were maintained in FTI groups compared with placebo (160\/40 mg vs. placebo: 6.2% treatment difference favoring FTI, P = 0.002 [primary endpoint]; 80\/20 mg vs. placebo: 7.5% treatment difference favoring FTI, P &amp;lt; 0.001). The treatment effect on mean PA sputum density was statistically significant for the FTI 80\/20 mg group versus placebo (\u22121.04 log10 \u00a0PA colony-forming units\/g sputum difference, favoring FTI; P = 0.01). Adverse events, primarily cough, were consistent with CF disease. Respiratory events, including dyspnea and wheezing, were less common with FTI 80\/20 mg than FTI 160\/40 mg. No clinically significant differences between groups were reported for laboratory values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>FTI maintained the substantial improvements in FEV1 % predicted achieved during the AZLI run-in and was well tolerated. FTI is a promising antipseudomonal therapy for patients with CF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201105-0924oc","type":"journal-article","created":{"date-parts":[[2011,11,18]],"date-time":"2011-11-18T00:51:43Z","timestamp":1321577503000},"page":"171-178","source":"Crossref","is-referenced-by-count":105,"title":["Fosfomycin\/Tobramycin for Inhalation in Patients with Cystic Fibrosis with\n                    <i>Pseudomonas<\/i>\n                    Airway Infection"],"prefix":"10.1093","volume":"185","author":[{"given":"Bruce C.","family":"Trapnell","sequence":"first","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio"},{"name":"University of Cincinnati Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna A.","family":"McColley","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Children's Memorial Hospital, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana G.","family":"Kissner","sequence":"additional","affiliation":[{"name":"Harper University Hospital, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Rolfe","sequence":"additional","affiliation":[{"name":"New Lungs Associates, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Albany Medical College, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"McKevitt","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Moorehead","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Bruce","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Geller","sequence":"additional","affiliation":[{"name":"Nemours Children's Clinic, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,1,15]]},"reference":[{"key":"2026032101125532100_bib1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"State of the art: pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101125532100_bib2","article-title":"2008 annual data report to the center directors","author":"Cystic Fibrosis Foundation Patient Registry","year":"2009"},{"key":"2026032101125532100_bib3","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0022-3476(97)70025-8","article-title":"Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis","volume":"131","author":"Corey","year":"1997","journal-title":"J Pediatr"},{"key":"2026032101125532100_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ppul.21198","article-title":"Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008","volume":"45","author":"Emerson","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"2026032101125532100_bib5","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2010.791","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"Dasenbrook","year":"2010","journal-title":"JAMA"},{"key":"2026032101125532100_bib6","doi-asserted-by":"crossref","first-page":"20529","DOI":"10.1073\/pnas.0709804104","article-title":"Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis","volume":"104","author":"Harris","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026032101125532100_bib7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/11316240-000000000-00000","article-title":"New antimicrobial strategies in cystic fibrosis","volume":"12","author":"van Westreenen","year":"2010","journal-title":"Paediatr Drugs"},{"key":"2026032101125532100_bib8","article-title":"TOBI (tobramycin inhalation solution, USP) [Internet]","author":"US Prescribing Information"},{"key":"2026032101125532100_bib9","article-title":"Cayston (aztreonam for inhalation solution) [Internet]","author":"US Prescribing Information"},{"key":"2026032101125532100_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"2026032101125532100_bib11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/infdis\/162.2.414","article-title":"Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation","volume":"162","author":"Daikos","year":"1990","journal-title":"J Infect Dis"},{"key":"2026032101125532100_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9343(90)90082-O","article-title":"Aminoglycoside nephrotoxicity","author":"Appel","year":"1990","journal-title":"Am J Med"},{"key":"2026032101125532100_bib13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ppul.20873","article-title":"Shifting patterns of inhaled antibiotic use in cystic fibrosis","volume":"43","author":"Moskowitz","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"2026032101125532100_bib14","author":"Tobramycin injection [package insert]","year":"2005"},{"key":"2026032101125532100_bib15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jac\/dkp282","article-title":"Antibacterial activities of a fosfomycin\/tobramycin combination: a novel inhaled antibiotic for bronchiectasis","volume":"64","author":"MacLeod","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2026032101125532100_bib16","author":"Fosfomycin tromethamine (Monurol) [package insert]","year":"2007"},{"key":"2026032101125532100_bib17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/jac\/24.5.657","article-title":"An increase in the antimicrobial activity in vitro of fosfomycin under anaerobic conditions","volume":"24","author":"Inouye","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"2026032101125532100_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jac\/48.2.209","article-title":"In vitro activity of fosfomycin in combination with various antistaphylococcal substances","volume":"48","author":"Grif","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2026032101125532100_bib19","first-page":"95","article-title":"In vitro activity of fosfomycin against \u2018problem\u2019 Gram-positive cocci","volume":"17","author":"Hamilton-Miller","year":"1992","journal-title":"Microbios"},{"key":"2026032101125532100_bib20","first-page":"320","article-title":"A phase 1 open label trial to assess the safety and tolerability of fosfomycin\/tobramycin for inhalation (FTI) in subjects with cystic fibrosis (CF) or bronchiectasis (BE) [abstract]","volume":"43","author":"Wilson","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"2026032101125532100_bib21","first-page":"321","article-title":"A phase 1 placebo-controlled, double-blind, randomized trial evaluating the safety and pharmacokinetics of three escalating doses of fosfomycin\/tobramycin for inhalation (FTI) in healthy volunteers [abstract]","volume":"43","author":"Wilson","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"2026032101125532100_bib22","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","article-title":"Development and validation of the cystic fibrosis questionnaire in the United States: a health related quality of life measure for cystic fibrosis","volume":"128","author":"Quittner","year":"2005","journal-title":"Chest"},{"key":"2026032101125532100_bib23","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"2026032101125532100_bib24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"2026032101125532100_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general US population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101125532100_bib26","article-title":"Categorical data analysis using the SAS system","author":"Koch","year":"2000","edition":"2nd edition"},{"key":"2026032101125532100_bib27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.111.4.955","article-title":"A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group","volume":"111","author":"Eisenberg","year":"1997","journal-title":"Chest"},{"key":"2026032101125532100_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ppul.1950070110","article-title":"Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa","volume":"7","author":"MacLusky","year":"1989","journal-title":"Pediatr Pulmonol"},{"key":"2026032101125532100_bib29","first-page":"327","article-title":"Aztreonam for inhalation solution (AZLI) vs. tobramycin inhalation solution (TIS): a 6-month comparative trial in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (PA) [abstract]","volume":"45","author":"Oermann","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"2026032101125532100_bib30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00228-010-0794-5","article-title":"Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria","volume":"66","author":"Kastoris","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"2026032101125532100_bib31","first-page":"325","article-title":"GS-9310\/11 Mechanism of action: enhanced inhibition of protein synthesis [abstract]","volume":"43","author":"MacLeod","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"2026032101125532100_bib32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1128\/AAC.39.1.34","article-title":"Macromolecular mechanisms of sputum inhibition of tobramycin activity","volume":"39","author":"Hunt","year":"1995","journal-title":"Antimicrob Agents Chemother"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/185\/2\/171\/67292937\/ajrccm_185_2_171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/185\/2\/171\/67292937\/ajrccm_185_2_171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:13:05Z","timestamp":1774069985000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/185\/2\/171\/8508103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,1,15]]},"published-print":{"date-parts":[[2012,1,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201105-0924oc","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13780962.15209061","asserted-by":"object"}]},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,1]]},"published":{"date-parts":[[2012,1]]}}}